Induction of labour
Queensland Clinical Guideline: Induction of labour

Document title: Induction of labour
Publication date: March 2017
Document number: MN17.22-V6-R22
Document supplement: The document supplement is integral to and should be read in conjunction with this guideline
Amendments: Full version history is supplied in the document supplement
Amendment date: June 2017
Replaces document: MN17.22-V5-R22
Author: Queensland Clinical Guidelines
Audience: Health professionals in Queensland public and private maternity and neonatal services
Review date: March 2022
Endorsed by: Queensland Clinical Guidelines Steering Committee
Statewide Maternity and Neonatal Clinical Network (Queensland)
Contact: Email: Guidelines@health.qld.gov.au
URL: www.health.qld.gov.au/qcg

Disclaimer

This guideline is intended as a guide and provided for information purposes only. The information has been prepared using a multidisciplinary approach with reference to the best information and evidence available at the time of preparation. No assurance is given that the information is entirely complete, current, or accurate in every respect.

The guideline is not a substitute for clinical judgement, knowledge and expertise, or medical advice. Variation from the guideline, taking into account individual circumstances, may be appropriate.

This guideline does not address all elements of standard practice and accepts that individual clinicians are responsible for:

- Providing care within the context of locally available resources, expertise, and scope of practice
- Supporting consumer rights and informed decision making in partnership with healthcare practitioners, including the right to decline intervention or ongoing management
- Advising consumers of their choices in an environment that is culturally appropriate and which enables comfortable and confidential discussion. This includes the use of interpreter services where necessary
- Ensuring informed consent is obtained prior to delivering care
- Meeting all legislative requirements and professional standards
- Applying standard precautions, and additional precautions as necessary, when delivering care
- Documenting all care in accordance with mandatory and local requirements

Queensland Health disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this guideline, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.

© State of Queensland (Queensland Health) 2017

This work is licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Australia. In essence, you are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute Queensland Clinical Guidelines, Queensland Health and abide by the licence terms. You may not alter or adapt the work in any way. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/3.0/au/deed.en
For further information, contact Queensland Clinical Guidelines, RBWH Post Office, Herston Qld 4029, email Guidelines@health.qld.gov.au, phone (07) 3131 6777. For permissions beyond the scope of this licence, contact: Intellectual Property Officer, Queensland Health, GPO Box 48, Brisbane Qld 4001, email ip_officer@health.qld.gov.au, phone (07) 3234 1479.
Flow Chart: Method of induction of labour

**Indication**
- Maternal and/or fetal benefit

**Contraindications**
- As for vaginal birth

**Communication with woman**
- Indication
- Maternal &/or fetal benefit & risk
- Individual circumstances
- Proposed IOL methods
- Options for pain management
- Options if:
  - IOL unsuccessful
  - IOL declined
  - Expectant management preferred
- Time for decision-making
- Obtain informed consent
- Document above

**Membrane sweep**
- Discuss antenatally
- Offer prior to IOL

If IOL declined or postponed
- Consider individual circumstances, woman's preferences, local service capabilities and priorities
- Perform maternal and fetal assessment
- Arrange ongoing monitoring
- From 42<sup>0</sup> weeks offer twice weekly:
  - CTG
  - USS for fetal wellbeing
- Provide verbal and written information on fetal movement
- Advise to contact health care provider if concerned
- Document assessment and plan of care in the health record

**Pre IOL assessment**
- Review history
- Confirm gestation
- Baseline observations
- Abdominal palpation (presentation, attitude, position, lie, engagement)
- CTG: consult obstetrician if abnormal
- Vaginal examination:
  - Assess MBS
  - Membrane status (intact or ruptured)

**Flow Diagram**

1. **Membranes ruptured?**
   - Yes
   - **ARM**
   - **Balloon catheter**
   - **Dinoprostone**
   - **Oxytocin**

2. **No**
   - MBS ≥ 7 (favourable)
   - Yes
   - **Refer to relevant flow chart**
   - No
     - **Previous CS?**
       - Yes
       - **Refer to relevant flow chart**
       - No
       - **ARM**
       - **Balloon catheter**
       - **Dinoprostone**
       - **Oxytocin**

**Modified Bishop Score (MBS)**

<table>
<thead>
<tr>
<th>Modified Bishop Score (MBS)</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cervical dilatation (cm)</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>Cervical length (cm)</td>
<td>&gt; 3</td>
<td>2</td>
<td>1</td>
<td>&lt; 1</td>
</tr>
<tr>
<td>Station (ischial spines)</td>
<td>– 3</td>
<td>– 2</td>
<td>– 1/0</td>
<td>+ 1/+ 2</td>
</tr>
<tr>
<td>Cervical consistency</td>
<td>Firm</td>
<td>Medium</td>
<td>Soft</td>
<td>-</td>
</tr>
<tr>
<td>Cervical position</td>
<td>Posterior</td>
<td>Mid</td>
<td>Anterior</td>
<td>-</td>
</tr>
</tbody>
</table>

Queensland Clinical Guidelines: F17.22-1-V5-R22

ARM Artificial rupture of membranes; cm centimetres; CS Caesarean section; CTG Cardiotocography; IOL Induction of labour; MBS Modified Bishop Score; USS Ultrasound scan; < less than; > greater than; ≥ greater than or equal to
Indications
- MBS ≤ 6
- Previous CS
- Following dinoprostone if no/minimal effect on cervical ripening and ARM not technically possible
- Reduced risk of uterine hyperstimulation is desirable

Contraindications
- Ruptured membranes
- Undiagnosed bleeding
- Simultaneous use of prostaglandins
- Low lying placenta
- Polyhydramnios
- Abnormal FHR auscultation or CTG

Relative contraindications
- Antepartum bleeding
- Lower tract genital infection
- Fetal head not engaged (4/5 or 5/5 above pelvic brim)

Insertion procedure
- Pre catheter insertion:
  - Ensure pre IOL assessment complete
  - Encourage to empty bladder
- Performed by medical or midwifery staff:
  - Contact a more experienced clinician if two unsuccessful attempts
- Inflate balloon catheters with sterile water or 0.9% sodium chloride:
  - Double balloon: 80 mL each balloon
  - Single balloon: 30–80 mL
- Document inflation volume

Post procedure observation and care
- Pulse, BP, FHR, uterine activity, engagement of fetal head and vaginal loss
  - Immediately, and repeat at 30 minutes
  - Medical review if malpresentation or fetal head 5/5 palpable after insertion
  - CTG not required (unless other indications)
- If observations normal, no contractions and not otherwise indicated, ongoing care as for latent first stage of labour
- Assess for/ask about discomfort

Moderate or severe discomfort?
- Labour commenced?
  - Yes: Labour care (Birth Suite)
  - No: Reduce balloon volume

Reduce balloon volume
- Remove 10 mL from each balloon
- Reassess and repeat to a minimum of 50 mL of residual volume in each balloon
- Document volume removed

Ongoing pain/discomfort?
- Yes: Moderate or severe discomfort?
  - Yes: If not in labour, offer analgesia and sedation
  - No: Labour care (Birth Suite) Ongoing care as indicated
- No: Labour care (Birth Suite) Ongoing care as indicated

Obstetric review
- Consider:
  - Dinoprostone, or
  - Reinsert catheter after 24 hours

Labour care (Birth Suite) Ongoing care as indicated

Continue IOL
- Recommend immediate commencement of oxytocin

12 hours after insertion:
- (Do not leave catheter in situ longer than 18 hours)
  - Reassess in birth suite
  - Recommend ARM

SROM?
- Yes: Any of the above
- No: Labour commenced?
  - Yes: Labour care (Birth Suite) Ongoing care as indicated
  - No: Moderator or severe discomfort?

Moderator or severe discomfort?
- If not in labour, offer analgesia and sedation

Ongoing pain/discomfort?
- Yes: Inspect balloon catheter
  - No: Armstrong (ARM) successful?
Queensland Clinical Guidelines: F17.22-3-V5-R22

Flow Chart: Prostaglandin E2 (dinoprostone)

**Indications**
- Unfavourable cervix (MBS ≤ 6)
- Following balloon catheter if no/minimal effect on cervical ripening and ARM not technically possible

**Contraindications**
- Known hypersensitivity
- Ruptured membranes
- Multiparity ≥ 5
- Previous CS or uterine surgery
- Malpresentation/high presenting part
- Undiagnosed PV bleeding
- Abnormal CTG/fetal compromise

**Cautions**
- Multiple pregnancy
- Asthma, chronic obstructive pulmonary disease: may cause bronchospasm
- Epilepsy
- Cardiovascular disease
- Raised intraocular pressure, glaucoma
- Avoid concurrent oxytocin use

**Post dose care**
- TPR, BP, FHR, uterine activity, PV loss hourly for 4 hours
- CTG for minimum of 30 minutes
- If observations normal, no contractions and not otherwise indicated, ongoing care as for latent first stage of labour
- Continuous CTG when in active labour or when contractions are ≥3 in 10 minutes
- After insertion advise woman to:
  - Remain recumbent for 30 minutes
  - Inform staff as soon as contractions commence

**PESSARY removal indications**
- Onset of regular, painful uterine contractions, occurring every 3 minutes regardless of cervical change
- Ruptured membranes
- Fetal distress
- Uterine hyperstimulation or hypertonic uterine contractions
- Maternal systemic adverse effects (e.g. nausea, vomiting, hypotension, tachycardia)

**Pre dinoprostone insertion**
- Complete pre IOL assessment
- Encourage to empty bladder

**Dinoprostone GEL**
- Nulliparous: 2 mg PV
- Multiparous: 1 mg PV
- Insert high into posterior fornix
- Wait at least 6 hours after insertion then reassess MBS

**Dinoprostone PESSARY**
- 10 mg PV
- Position transversely in posterior fornix
- Wait at least 12 hours after insertion then reassess MBS

**Recommend ARM irrespective of MBS**

**If GEL used:**
- May repeat to maximum of 3 doses at least 6 hours apart
  - Nulliparous 2 mg
  - Multiparous 1–2 mg
- Wait at least 6 hours then reassess MBS

**If PESSARY used:**
- Give one dose of dinoprostone GEL
- Wait at least 6 hours then reassess MBS

**Consider balloon catheter**

**Recommend oxytocin**
- 6 hours after GEL
- 30 minutes after removal of PESSARY (minimum)

**ARM** Artificial rupture of membranes; **BP** Blood pressure; **CS** Caesarean section; **CTG** Cardiotocography; **FHR** Fetal heart rate; **IOL** Induction of labour; **MBS** Modified Bishop Score; **PV** Per vaginam; **SROM** Spontaneous rupture of membranes; **TPR** Temperature, pulse and respirations; ≥ greater than or equal to; ≤ less than or equal to
Flow Chart: Artificial rupture of membranes

Indications
- After cervical ripening method
- Favourable cervix (MBS ≥ 7)
- Before oxytocin infusion commenced

Relative contraindications
- Poor application of the presenting part/unstable lie
- Fetal head not engaged

Post ARM care
- Immediately after procedure document:
  - Abdominal palpation
  - VE findings
  - FHR
  - Uterine activity
  - Vaginal loss (liquor amount, colour consistency)
- If oxytocin commenced, monitor as for oxytocin
- If oxytocin not commenced and observations normal and no contractions, then ongoing monitoring as for latent first stage
- If FHR or liquor abnormalities discuss/refer/consult
- Encourage mobilisation to promote onset of uterine contractions

Pre ARM
- Complete pre IOL assessment
- Encourage to empty bladder
- Abdominal palpation to determine:
  - Descent
  - Position
  - Presentation

VE to identify:
- Stage of labour
- MBS
- Presentation
- Position and descent
- Membranes

Assess for clinical concerns:
- Polyhydramnios
- Head not engaged
- Malpresentation
- Possible cord presentation
- Unstable lie

Clinical concerns identified?

Yes

ARM
- Continue to ARM from assessment VE
- Confirm passage of fluid and check for presence of blood and meconium
- Ensure good application of presenting part before completing VE
- FHR immediately following procedure

No

FHR or liquor abnormalities?

Yes

Recommend immediate commencement of oxytocin

CTG
Discuss, refer or consult as indicated

Consult obstetrician

No
Inductions

- IOL with ruptured membranes

Cautions

- Do not commence oxytocin within:
  - 6 hours of dinoprostone gel
  - 30 minutes of removal of dinoprostone pessary
- Discuss with obstetrician if:
  - Previous uterine surgery (e.g., CS)
  - Multiple pregnancy
  - More than 4 previous births
  - Cardiovascular disease

Potential side effects

- Uterine hyperstimulation
- Nausea and vomiting
- Water intoxication or hyponatremia with prolonged infusion (rare with isotonic infusion)
- Primary postpartum haemorrhage
- If planned VBAC: uterine dehiscence and rupture
- Rarely (< 0.1%) arrhythmias, ECG changes, anaphylaxis, tetanic contractions, transient hypotension, reflex tachycardia

Oxytocin administration:

- Via sideline/secondary IV access
- Volumetric pump required
- Record dose in milliunit/minute

Observation and care

- Provide one-to-one midwifery care
- Commence intrapartum record
- Commence continuous CTG at the onset of first contractions
- Maternal and fetal observations as per first stage of active labour
- Maintain fluid balance chart

Dose management

- Use minimum dose required to establish and maintain active labour
- Maternal and FHR prior to any increase
- Aim for contractions:
  - 3–4 in a 10 minute period
  - Duration of 40–60 seconds
  - Resting period not less than 60 seconds
- Titrate against uterine contractions
- Increase at 30 minute or longer intervals
- Obstetric review required:
  - Prior to exceeding 20 milliunit/minute
  - At 32 milliunit/minute if labour has not commenced
  - If infusion ceased
- Document changes to dose clearly and contemporaneously on the intrapartum record and/or CTG

If recommencing infusion

- Consult with an obstetrician
- If ceased for less than 30 minutes, recommence at half the previous rate
- If ceased for greater than 30 minutes, recommence at initial starting dose

Indication of labour

See flowchart: Method of induction

Pre oxytocin commencement:

- Complete pre IOL assessment
- Verify CTG normal
- If membranes intact, perform ARM

Potential side effects

- Uterine hyperstimulation
- Nausea and vomiting
- Water intoxication or hyponatremia with prolonged infusion (rare with isotonic infusion)
- Primary postpartum haemorrhage
- If planned VBAC: uterine dehiscence and rupture
- Rarely (< 0.1%) arrhythmias, ECG changes, anaphylaxis, tetanic contractions, transient hypotension, reflex tachycardia

Infusion: oxytocin

(30 International units in 500 mL)

1 milliunit/minute = 1 mL/hour

<table>
<thead>
<tr>
<th>Time after starting (minutes)</th>
<th>Dose (milliunit/minute)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>30</td>
<td>2</td>
</tr>
<tr>
<td>60</td>
<td>4</td>
</tr>
<tr>
<td>90</td>
<td>8</td>
</tr>
<tr>
<td>120</td>
<td>12</td>
</tr>
<tr>
<td>150</td>
<td>16</td>
</tr>
<tr>
<td>180</td>
<td>20</td>
</tr>
<tr>
<td>Prior to exceeding 20 milliunit/minute obstetric review required</td>
<td></td>
</tr>
<tr>
<td>210</td>
<td>24</td>
</tr>
<tr>
<td>240</td>
<td>28</td>
</tr>
<tr>
<td>270</td>
<td>32</td>
</tr>
</tbody>
</table>

Prior to exceeding 20 milliunit/minute obstetric review required

Queensland Clinical Guidelines: F17.22-5-V5-R22

ARM Artificial rupture of membranes; CS Caesarean section; CTG Cardiotocography; ECG Electrocardiograph; FHR Fetal heart rate; IOL Induction of labour; IV Intravenous; VBAC Vaginal birth after caesarean section; < less than; ≥ greater than or equal to
### Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARM</td>
<td>Artificial rupture of membranes</td>
</tr>
<tr>
<td>BP</td>
<td>Blood pressure</td>
</tr>
<tr>
<td>CI</td>
<td>Confidence interval</td>
</tr>
<tr>
<td>CS</td>
<td>Caesarean section</td>
</tr>
<tr>
<td>CTG</td>
<td>Cardiotocography</td>
</tr>
<tr>
<td>EFW</td>
<td>Estimated fetal weight</td>
</tr>
<tr>
<td>FGR</td>
<td>Fetal growth restriction</td>
</tr>
<tr>
<td>FHR</td>
<td>Fetal heart rate</td>
</tr>
<tr>
<td>IOL</td>
<td>Induction of labour</td>
</tr>
<tr>
<td>MBS</td>
<td>Modified Bishop Score</td>
</tr>
<tr>
<td>NICU</td>
<td>Neonatal intensive care unit</td>
</tr>
<tr>
<td>NNT</td>
<td>Number needed to treat</td>
</tr>
<tr>
<td>PGE2</td>
<td>Prostaglandin E2</td>
</tr>
<tr>
<td>PPH</td>
<td>Primary postpartum haemorrhage</td>
</tr>
<tr>
<td>PV</td>
<td>Per vaginam</td>
</tr>
<tr>
<td>RCT</td>
<td>Randomised controlled trial</td>
</tr>
<tr>
<td>RR</td>
<td>Risk ratio</td>
</tr>
<tr>
<td>SROM</td>
<td>Spontaneous rupture of membranes</td>
</tr>
<tr>
<td>TPR</td>
<td>Temperature, pulse, respiration</td>
</tr>
<tr>
<td>USS</td>
<td>Ultrasound scan</td>
</tr>
<tr>
<td>VBAC</td>
<td>Vaginal birth after caesarean</td>
</tr>
<tr>
<td>VE</td>
<td>Vaginal examination</td>
</tr>
<tr>
<td>VTE</td>
<td>Venous thromboembolism</td>
</tr>
<tr>
<td>x+y</td>
<td>x is number of completed weeks of pregnancy +y is the number of days past the number of completed weeks of pregnancy (e.g. 40+3 is 40 completed weeks of pregnancy plus 3 days)</td>
</tr>
</tbody>
</table>

### Definition of terms

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amniotomy</td>
<td>Artificial rupture of membranes to initiate or speed up labour.¹</td>
</tr>
<tr>
<td>Balloon catheter</td>
<td>A flexible tube with an inflatable balloon at one end. This can be introduced through the cervix and the balloon inflated, holding the catheter in place. Also known as transcervical catheter</td>
</tr>
<tr>
<td>Cervical ripening</td>
<td>A prelude to the onset of labour whereby the cervix becomes soft and compliant. This allows its shape to change from being long and closed, to being thinned out (effaced) and starting to open (dilate). It either occurs naturally or as a result of physical or pharmacological interventions.¹</td>
</tr>
<tr>
<td>Expectant management</td>
<td>Allowing labour to develop and progress under supervision without intervention, unless clinically indicated.¹</td>
</tr>
<tr>
<td>Favourable cervix</td>
<td>The cervix is said to be favourable when its characteristics suggest there is a high chance of spontaneous onset of labour, or of responding to interventions made to induce labour.¹</td>
</tr>
<tr>
<td>Fetal growth restriction</td>
<td>Also known as intrauterine growth restriction (IUGR). Fetal growth restriction (FGR) indicates the presence of a pathophysiological process occurring in utero that inhibits fetal growth.²</td>
</tr>
<tr>
<td>Grand multipara</td>
<td>A woman who has given birth to five or more babies.</td>
</tr>
<tr>
<td>Induction of labour</td>
<td>The process of artificially initiating labour.¹</td>
</tr>
<tr>
<td>Mechanical method</td>
<td>Non-pharmacological method of inducing labour.¹</td>
</tr>
<tr>
<td>Obstetrician</td>
<td>Local facilities may differentiate the roles and responsibilities assigned in this document to an “Obstetrician” according to their specific practitioner group requirements; for example to General Practitioner Obstetricians, Specialist Obstetricians, Consultants, Visiting Medical Officers, Senior Registrars, Obstetric Fellows or other members of the team as required.</td>
</tr>
<tr>
<td>Prolonged pregnancy</td>
<td>A pregnancy past 42⁷/₀ weeks gestation.¹</td>
</tr>
<tr>
<td>Transcervical catheter</td>
<td>Refer to the definition for balloon catheter.</td>
</tr>
<tr>
<td>Uterine hyperstimulation</td>
<td>Either uterine tachysystole or uterine hypertonus with FHR abnormalities.²</td>
</tr>
<tr>
<td>Uterine hypertonus</td>
<td>Contractions lasting more than two minutes in duration or contractions occurring within 60 seconds of each other, without fetal heart rate abnormalities.³</td>
</tr>
<tr>
<td>Uterine tachysystole</td>
<td>More than 5 contractions in 10 minutes without FHR abnormalities.²</td>
</tr>
</tbody>
</table>
Table of Contents

1 Introduction .................................................................................................................. 10
  1.1 Communication and information ........................................................................... 10
  1.2 IOL declined or postponed .................................................................................... 11
  1.3 Clinical standards .................................................................................................. 11
2 Specific indications and circumstances ........................................................................ 12
  2.1 Prolonged pregnancy prevention ............................................................................ 12
  2.2 Concern for fetal wellbeing ..................................................................................... 12
  2.3 Twin pregnancy ........................................................................................................ 13
  2.4 Fetal macrosomia ..................................................................................................... 13
  2.5 Advanced maternal age ........................................................................................... 13
  2.6 Obstetric cholestasis (intrahepatic cholestasis of pregnancy) ................................. 14
  2.7 Maternal ethnicity .................................................................................................. 14
  2.8 Maternal request ..................................................................................................... 14
3 Pre IOL assessment ....................................................................................................... 15
  3.1 Cervical assessment ................................................................................................ 15
  3.2 Membrane sweeping ............................................................................................... 16
4 Methods of IOL ............................................................................................................ 17
  4.1 Balloon (transcervical) catheter ............................................................................. 18
    4.1.1 Balloon (transcervical) catheter insertion ......................................................... 19
    4.1.2 Balloon (transcervical) catheter post insertion care .................................... 20
  4.2 Dinoprostone ........................................................................................................... 21
    4.2.1 Dinoprostone administration ........................................................................... 22
  4.3 Artificial rupture of membranes ............................................................................. 23
  4.4 Oxytocin .................................................................................................................. 24
    4.4.1 Oxytocin regimen administration .................................................................. 25
5 Risks and benefits associated with IOL ....................................................................... 26
References ....................................................................................................................... 27
Acknowledgements .......................................................................................................... 30

List of Tables

Table 1. Communication and information-........................................................................ 10
Table 2. IOL declined or postponed ................................................................................ 11
Table 3. Clinical standards .............................................................................................. 11
Table 4. Prolonged pregnancy ......................................................................................... 12
Table 5. Fetal growth restriction .................................................................................... 12
Table 6. Twin pregnancy ................................................................................................ 13
Table 7. Suspected fetal macrosomia .............................................................................. 13
Table 8. Advanced maternal age .................................................................................... 13
Table 9. Obstetric cholestasis ......................................................................................... 14
Table 10. Maternal ethnicity .......................................................................................... 14
Table 11. Maternal request ............................................................................................ 14
Table 12. Modified Bishop score .................................................................................... 15
Table 13. Membrane sweeping ..................................................................................... 16
Table 14. Methods of IOL .............................................................................................. 17
Table 15. Balloon catheter considerations ..................................................................... 18
Table 16. Balloon catheter insertion procedure ............................................................. 19
Table 17. Post balloon catheter insertion ....................................................................... 20
Table 18. Dinoprostone considerations and dose .......................................................... 21
Table 19. Dinoprostone administration .......................................................................... 22
Table 20. Artificial rupture of membranes ...................................................................... 23
Table 21. Oxytocin .......................................................................................................... 24
Table 22. Oxytocin administration ................................................................................. 25
Table 23. Oxytocin regimen ........................................................................................... 25
Table 24. Risks and benefits associated with IOL .......................................................... 26
1 Introduction

Induction of labour (IOL) is the initiation of contractions in a pregnant woman who is not in labour. IOL is indicated when the maternal and/or fetal risks of ongoing pregnancy outweigh the risks of IOL and birth. Contraindications to IOL are consistent with those for vaginal birth. A woman’s individual circumstances and preferences will influence the timing and method of IOL. In 2014 the IOL rate in Queensland was 24.9% of all births.4

The purpose of this guideline is to guide the IOL process in women at or near term. Refer to associated Queensland Clinical Guidelines for specific circumstances outside the scope of this guideline including:

- Early pregnancy loss5
- Therapeutic termination of pregnancy6
- Perinatal care at the threshold of viability7
- Stillbirth care8

1.1 Communication and information

Discuss the risks and benefits of IOL as they pertain to each individual woman. Take into account individual needs and preferences, to enable the woman to make an informed decision in consultation with her health care provider.9

Table 1. Communication and information-

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Good practice points</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal experience</td>
<td>• Provide time for questions and decision making</td>
</tr>
<tr>
<td></td>
<td>• In 2014–2015 in Queensland, for women who had an IOL:</td>
</tr>
<tr>
<td></td>
<td>o 27% reported having made an informed decision10</td>
</tr>
<tr>
<td></td>
<td>o 91% felt the reasons for the IOL were explained in a way they could understand11</td>
</tr>
<tr>
<td></td>
<td>o 21% felt they had no choice about whether their labour would be induced11</td>
</tr>
<tr>
<td>IOL discussion points</td>
<td>• Indication for IOL</td>
</tr>
<tr>
<td></td>
<td>• Method of IOL</td>
</tr>
<tr>
<td></td>
<td>• Potential risks and benefits</td>
</tr>
<tr>
<td></td>
<td>o Refer to Section 5 Risks and benefits associated with IOL</td>
</tr>
<tr>
<td></td>
<td>• Options for pain relief</td>
</tr>
<tr>
<td></td>
<td>• Options if unsuccessful</td>
</tr>
<tr>
<td></td>
<td>• Options if declined</td>
</tr>
<tr>
<td>Written/online information</td>
<td>• Consider the use of decision aids to assist the woman make informed choices12</td>
</tr>
<tr>
<td></td>
<td>o Refer to Queensland Clinical Guideline parent information: Induction of labour13</td>
</tr>
<tr>
<td>Documentation</td>
<td>• Clear and contemporaneous documentation is required in the healthcare record including:</td>
</tr>
<tr>
<td></td>
<td>o The indication for IOL</td>
</tr>
<tr>
<td></td>
<td>o The content and outcome of discussions [refer to discussion points above]</td>
</tr>
<tr>
<td></td>
<td>o Informed consent/choice</td>
</tr>
<tr>
<td></td>
<td>o Care provided (e.g. Bishop score, observations)</td>
</tr>
<tr>
<td></td>
<td>o Clinician signature and designation</td>
</tr>
</tbody>
</table>
1.2 IOL declined or postponed

Table 2. IOL declined or postponed

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Good practice points</th>
</tr>
</thead>
</table>
| **Communication** | • If IOL is declined, respect the woman’s decision  
• Where pregnancy gestation was greater than 41 weeks gestation, women who:  
  o Waited for labour to start~38% would choose to wait next time  
  o Were induced~73% would choose IOL next time  
• No form of increased antenatal monitoring has been shown to reduce perinatal mortality associated with prolonged pregnancy  
| **Plan care** | • If IOL is declined or postponed (e.g. due to resourcing issues or as a result of maternal request), take into account the:  
  o Individual clinical circumstances and preferences  
  o Indication for IOL  
  o Local service capabilities and priorities  
• Perform an assessment of maternal and fetal wellbeing  
• Develop a plan with the woman for continued care including:  
  o Arrangements for ongoing monitoring  
  o Return for IOL  
• From 42+0 weeks offer at least twice weekly assessment for fetal wellbeing, including:  
  o Cardiotocography (CTG)  
  o Ultrasound scan (USS) assessment of amniotic fluid volume using estimation of deepest vertical pocket  
  o Refer to Section 2.1 Prolonged pregnancy prevention  
• Advise the woman to contact her health care provider/facility if concerned about her wellbeing or that of her baby (including not to wait until the next day)  
• Provide verbal and written information about fetal movements  
• Document the discussion, assessment and plan in the health record |

1.3 Clinical standards

Table 3. Clinical standards

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Good practice points</th>
</tr>
</thead>
</table>
| **Service capabilities** | • Provide care in the context of the Clinical Services Capability Framework  
• Ensure availability of health care professionals appropriate to the circumstances  
• Continuous electronic fetal heart monitoring and uterine contraction monitoring is required for IOL with oxytocin and prostaglandin  
• Establish quality and safety programs and tools to monitor care (e.g. IOL safety audits and reviews)  
• Provide care in accordance with the national consensus statement  
| **Outpatient setting** | • There is insufficient evidence to determine if IOL is effective and safe in outpatient settings  
• If a facility provides outpatient IOL prior to the onset of established labour (e.g. for cervical ripening), develop local protocols to support:  
  o Appropriate clinical governance, clinical indications, inclusion/exclusion criteria, written information for women, observation/monitoring protocols and adequate follow-up and support for women  
  o In the outpatient setting, IOL with balloon catheters may be safer than IOL with prostaglandins as studies show less uterine hyperstimulation during the cervical ripening phase  

2 Specific indications and circumstances

Refer to associated Queensland Clinical Guidelines, which include IOL considerations for the specific maternal circumstances of:

- Hypertensive disorders of pregnancy\(^{22}\)
- Gestational diabetes mellitus\(^{23}\)
- Obesity in pregnancy\(^{24}\)
- Vaginal birth after caesarean (VBAC)\(^{25}\)
- Early onset Group B Streptococcal disease (EOGBSD)\(^{26}\), includes information related to:
  - Prelabour rupture of membranes
  - Preterm prelabour rupture of membranes
- Stillbirth care\(^{8}\)
- Venous thromboembolism (VTE) prophylaxis in pregnancy and the puerperium\(^{27}\)
- Perinatal substance use: maternal\(^{28}\)

Considerations for other IOL indications and circumstances are outlined in the following sections.

### 2.1 Prolonged pregnancy prevention

Table 4. Prolonged pregnancy

<table>
<thead>
<tr>
<th>Prevention of prolonged pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Risk/Benefit</strong></td>
</tr>
</tbody>
</table>
| No form of increased antenatal monitoring has been shown to reduce perinatal mortality associated with prolonged pregnancy\(^{15}\).  
IOL from 41\(^{+}0\) weeks, compared with expectant management, is associated with\(^{15}\):  
  - Fewer perinatal deaths [0.4 versus 3.2 per 1000 women]  
  - Less meconium aspiration syndrome [40 versus 66 per 1000 newborns]  
  - No difference in neonatal intensive care (NICU) admissions  
  - Fewer caesarean sections (CS) [168 versus 225 per 1000 women]  
  - Most women prefer IOL at 41 weeks over serial antenatal monitoring\(^{14}\). |
| **Clinical practice point**        |
| For uncomplicated pregnancies, recommend IOL after 41\(^{+}0\) weeks\(^{1,16,29}\).  
Exact timing depends on the specific risk of stillbirth, individual preferences and local circumstances\(^{1}\).  
Waiting after 42\(^{+}0\) weeks is not recommended\(^{1,30}\). |

### 2.2 Concern for fetal wellbeing

Concern for fetal wellbeing may arise with FGR/small for gestational age [refer to Table 5], decreased fetal movements, oligohydramnios, non-reassuring fetal surveillance test, fetal abnormality, or isoimmunisation. The timing of birth may depend on gestational age, severity of concern and results of tests of fetal wellbeing. Increased fetal surveillance may be required with expectant management [refer to Section 1.2 IOL declined or postponed].

Table 5. Fetal growth restriction

<table>
<thead>
<tr>
<th>Fetal growth restriction</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Risk/Benefit</strong></td>
</tr>
</tbody>
</table>
| Although underpowered to show differences in late pregnancy loss, for term FGR, comparing IOL with expectant monitoring, studies show no significant difference in\(^{31,32}\):  
  - Rate of obstetric interventions (e.g. CS)  
  - Maternal or neonatal morbidity and mortality  
  - Admission to a neonatal unit if birth occurred after 38 weeks gestation |
| **Clinical practice point** |
| For babies with FGR, use of umbilical artery, middle cerebral and ductus venosus Doppler may assist in improving perinatal outcome through more appropriate timing of birth\(^{33,34}\).  
Severity affects the decision concerning mode and timing of birth\(^{35}\).  
If recommending expectant management, increase fetal surveillance [refer to Section 1.2 IOL declined or postponed].  
IOL at term to prevent stillbirth is appropriate |
2.3 Twin pregnancy

Table 6. Twin pregnancy

<table>
<thead>
<tr>
<th>Risk/Benefit</th>
<th>Twin pregnancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Based on data from the United States, the fetal/infant mortality per additional week of expectant management at(^{36}):</td>
<td></td>
</tr>
<tr>
<td>o 37 weeks is 4.39 per 1000 women 95% CI 4.07 to 4.70</td>
<td></td>
</tr>
<tr>
<td>o 38 weeks is 5.92 per 1000 women 95% CI 5.40 to 6.43</td>
<td></td>
</tr>
<tr>
<td>• A Cochrane review of elective birth at 37 weeks compared to expectant management demonstrated(^ {37} ):</td>
<td></td>
</tr>
<tr>
<td>o No statistically significant differences in CS, perinatal death or serious morbidity, maternal death or serious maternal morbidity</td>
<td></td>
</tr>
<tr>
<td>o Significant reduction in risk of babies being born with a birth weight less than the third percentile [one study; RR 0.30; 95% CI 0.13 to 0.68]</td>
<td></td>
</tr>
<tr>
<td>• Monochorionic twins are at increased risk of stillbirth in the third trimester (^{38})</td>
<td></td>
</tr>
</tbody>
</table>

Clinical practice point

- In uncomplicated twin pregnancies (monochorionic\(^ {39,40}\) or dichorionic), plan birth after 37+0 weeks \(^ {36,37,41}\)

2.4 Fetal macrosomia

Table 7. Suspected fetal macrosomia

<table>
<thead>
<tr>
<th>Consideration</th>
<th>Fetal macrosomia</th>
</tr>
</thead>
<tbody>
<tr>
<td>• In a Cochrane review, comparing IOL at 37–40 weeks to expectant management, there were(^ {42}):</td>
<td></td>
</tr>
<tr>
<td>o No significant differences in:</td>
<td></td>
</tr>
<tr>
<td>▪ CS rate or instrumental birth</td>
<td></td>
</tr>
<tr>
<td>▪ Measures of neonatal asphyxia</td>
<td></td>
</tr>
<tr>
<td>o Lower risks of shoulder dystocia, and (any) fracture (NNT=60)</td>
<td></td>
</tr>
<tr>
<td>o Lower birth weights [178.03 g, 95% CI 40.81 to 315.26]</td>
<td></td>
</tr>
<tr>
<td>o Higher incidences of third and fourth degree perineal tears (one study)</td>
<td></td>
</tr>
</tbody>
</table>

Clinical practice point

- IOL on the basis of clinical suspicion of macrosomia alone is not recommended\(^ {1}\)
- USS for estimated fetal weight (EFW) is advised\(^ {43}\)
- With a suspected large for gestation age baby based on clinical assessment (e.g. symphysio-fundal height equals 3 cm more than expected from 36 weeks), offer an USS to measure EFW\(^ {43}\)
- Discuss IOL after 38\(^ {15}\) weeks if EFW greater than\(^ {43}\): |
| o 3500 g at approximately 36 weeks |
| o 3700 g at approximately 37 weeks |
| o 3900 g at approximately 38 weeks |

2.5 Advanced maternal age

Table 8. Advanced maternal age

<table>
<thead>
<tr>
<th>Risk/Benefit</th>
<th>Advanced maternal age</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Advanced maternal age is an independent risk factor for stillbirth(^ {44,45,46}):</td>
<td></td>
</tr>
<tr>
<td>o Nulliparous women may be at higher risk of stillbirth, but evidence is inconsistent(^ {45,47})</td>
<td></td>
</tr>
<tr>
<td>• IOL at 39 weeks for advanced maternal age, compared to expectant management, had no significant effect on the CS rate and no adverse short-term effects on maternal and neonatal outcomes(^ {48})</td>
<td></td>
</tr>
</tbody>
</table>

Clinical practice point

- For women aged 40 years or older, offer IOL at 39\(^ {15}\)–40\(^ {14}\) weeks gestation\(^ {45,49}\)
2.6 Obstetric cholestasis (intrahepatic cholestasis of pregnancy)

Table 9. Obstetric cholestasis

<table>
<thead>
<tr>
<th>Obstetric cholestasis</th>
<th>Risk/Benefit</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Associated with:</td>
<td></td>
</tr>
<tr>
<td>o Stillbirth(^{50,51})</td>
<td></td>
</tr>
<tr>
<td>▪ Approximately 1.2% after 37 weeks gestation (although this may be consistent with population stillbirth rates(^{52}))</td>
<td></td>
</tr>
<tr>
<td>o Increases with increasing gestational age and bile acid levels</td>
<td></td>
</tr>
<tr>
<td>o Meconium stained liquor(^{50,51})</td>
<td></td>
</tr>
<tr>
<td>o Preterm birth(^{50,51})</td>
<td></td>
</tr>
<tr>
<td>• No quality evidence exists to guide timing of birth(^{50,53}) although IOL is often recommended between 37 to 38 weeks(^{54}) due to risk of stillbirth</td>
<td></td>
</tr>
<tr>
<td>• Identified as a medical indication for late preterm (34(^{10})–36(^{16}) weeks gestational age) or early term (37(^{40})–38(^{46}) weeks gestational age) birth by American College of Obstetricians and Gynaecologists(^{55})</td>
<td></td>
</tr>
</tbody>
</table>

Clinical practice point

• Consider IOL between 37\(^{10}\) and 37\(^{16}\) weeks gestation as relevant to\(^{35}\):
  o Individual circumstances—case for intervention is stronger with more severe biochemical abnormalities
  o Risk of stillbirth—cannot predict if pregnancy continues
  o Higher risk of neonatal respiratory morbidity from early intervention
• Offer continuous fetal monitoring during labour
• Consider IOL around 36 weeks for severe cases with jaundice, progressive elevations in serum bile acids and liver enzymes, and suspected fetal compromise\(^{56}\)

2.7 Maternal ethnicity

Table 10. Maternal ethnicity

<table>
<thead>
<tr>
<th>Maternal ethnicity</th>
<th>Consideration</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Differences in ethnicity have been reported in perinatal mortality data(^{57-63}) but whether this is entirely attributable to genetic factors is unclear</td>
<td></td>
</tr>
<tr>
<td>• In one retrospective study, South-Asian born women (country of birth India, Sri Lanka, Bangladesh, Pakistan) compared to Australian-born women:</td>
<td></td>
</tr>
<tr>
<td>o Had a higher antepartum stillbirth rate [2.4 times more likely, 95% CI 1.4 to 4.0] with risk increasing progressively with gestation</td>
<td></td>
</tr>
<tr>
<td>o Were twice as likely to have a low birthweight baby (less than 2500 g)</td>
<td></td>
</tr>
</tbody>
</table>

Clinical practice point

• Insufficient evidence to recommend IOL based on maternal ethnicity alone
• Consider a woman’s ethnicity in the context of other risk factors when determining timing of IOL

2.8 Maternal request

Table 11. Maternal request

<table>
<thead>
<tr>
<th>Maternal request</th>
<th>Risk/Benefit</th>
</tr>
</thead>
<tbody>
<tr>
<td>• For low risk women elective IOL at term is not associated with an increased risk of CS(^{64})</td>
<td></td>
</tr>
<tr>
<td>• The long term population consequences of a significant proportion of low risk women receiving elective IOL are unknown</td>
<td></td>
</tr>
<tr>
<td>• IOL requires more intensive clinical resources than spontaneous onset of labour in low risk women</td>
<td></td>
</tr>
<tr>
<td>• Retrospective and population based studies suggest a possible association between birth prior to 39 weeks and developmental/early childhood health problems(^{52,68})</td>
<td></td>
</tr>
</tbody>
</table>

Clinical practice point

• Consider IOL at term based on exceptional circumstances of the woman and her family (i.e. not solely because of patient or health care provider preference\(^{5}\))
3 Pre IOL assessment

Immediately prior to IOL:

- Review maternal history
- Confirm gestation
- Perform baseline maternal observations (e.g. temperature pulse, respiratory rate and blood pressure)
- Perform abdominal palpation to confirm presentation, attitude, lie, position, and engagement
- Assess membrane status (ruptured or intact)
- Vaginal examination (VE) to assess the cervix [refer to Section 3.1 Cervical assessment]
- Assess fetal wellbeing:
  - FHR
  - Confirm CTG is normal
  - If CTG abnormal, escalate as per local protocols
  - Refer to Queensland Clinical Guideline: Intrapartum fetal surveillance
- Assess for contraindications to IOL
- Consider urgency for IOL

3.1 Cervical assessment

The Bishop score is commonly used to assess the cervix and to inform the choice of method of IOL. Each feature of the cervix is scored and then the scores are summed [refer Table 12]. The state of the cervix is one of the important predictors of successful IOL. The cervix is unfavourable if the MBS is 6 or less.

Table 12. Modified Bishop score

<table>
<thead>
<tr>
<th>Cervical feature</th>
<th>Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dilation (cm)</td>
<td>0</td>
</tr>
<tr>
<td>Length of cervix (cm)</td>
<td>&gt; 3</td>
</tr>
<tr>
<td>Station (relative to ischial spines)</td>
<td>− 3</td>
</tr>
<tr>
<td>Consistency</td>
<td>Firm</td>
</tr>
<tr>
<td>Position</td>
<td>Posterior</td>
</tr>
</tbody>
</table>
3.2 Membrane sweeping

Membrane sweeping refers to the digital separation of the fetal membranes from the lower uterine segment during VE. This movement helps to separate the cervix from the membranes and stimulate the release of prostaglandins.

Table 13. Membrane sweeping

<table>
<thead>
<tr>
<th>Membrane sweeping</th>
<th>Indication</th>
<th>Contraindication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>• Reduce the need for IOL by encouraging spontaneous labour</td>
<td>• Consistent with contraindications for vaginal birth[71]</td>
</tr>
<tr>
<td></td>
<td>• Optimal gestation at which to commence is controversial[71]</td>
<td>• Preterm gestation</td>
</tr>
<tr>
<td>Risk/Benefit</td>
<td>• Serial membrane sweeping (every 2 days) reduced the number of pregnancies reaching 42 weeks [NNT=672]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• When performed at the onset of formal induction, membrane sweeping resulted in shorter induction to birth interval, shorter duration of oxytocin infusion and improved birth process satisfaction[73,74]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Reduced need for IOL, particularly in multiparous women[72]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Optimal frequency is unknown[71]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• No evidence of increased risk of maternal or neonatal infection[71,75]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Is as safe in Group B Streptococcus (GBS) positive women as for women whose GBS status is unknown or negative[71,76]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• No data available on HIV or hepatitis C[71]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Associated with discomfort[72,75], vaginal bleeding and irregular contractions[75]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Some studies have shown no difference in cervical length, time to onset of labour, or duration of the active phase of labour, where VBAC is planned[71,77,78]</td>
<td></td>
</tr>
<tr>
<td>Clinical practice point</td>
<td>• Discuss the benefits of membrane sweeping in the antenatal period</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Offer prior to formal IOL[71]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• If the cervix is closed and membrane sweeping is not possible, cervical massage in vaginal fornices may achieve similar effect[1]</td>
<td></td>
</tr>
</tbody>
</table>
### 4 Methods of IOL

#### Table 14. Methods of IOL

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cervical ripening for unfavourable cervix</strong></td>
<td>• Mechanical: balloon (transcervical) catheter (e.g. Foley, Cook cervical ripening balloon)</td>
</tr>
<tr>
<td></td>
<td>• Pharmacological: dinoprostone preparations (prostaglandin E&lt;sub&gt;2&lt;/sub&gt;/prostin gel, cervidil)</td>
</tr>
<tr>
<td><strong>After cervical ripening/cervix favourable</strong></td>
<td>• Artificial rupture of membranes (ARM)</td>
</tr>
<tr>
<td></td>
<td>• Oxytocin</td>
</tr>
<tr>
<td><strong>If primary cervical ripening method is unsuccessful</strong></td>
<td>• If primary method was:</td>
</tr>
<tr>
<td></td>
<td>o Balloon catheter consider Dinoprostone gel/pessary</td>
</tr>
<tr>
<td></td>
<td>o Dinoprostone gel up to 3 doses consider Balloon catheter</td>
</tr>
<tr>
<td></td>
<td>o Dinoprostone pessary consider Dinoprostone gel or balloon catheter</td>
</tr>
<tr>
<td><strong>Insufficient evidence</strong></td>
<td>• For IOL—there is insufficient evidence to support Laminaria tents, breast/nipple stimulation (particularly if high risk), acupuncture, sexual intercourse, evening primrose oil, homeopathy, castor oil, nitric oxide donors, hyaluronidase, oestrogen, and corticosteroids.</td>
</tr>
<tr>
<td><strong>Misoprostol</strong></td>
<td>• Compared with placebo, misoprostol (sustained release vaginal pessary, vaginal tablet, buccal/sublingual and oral tablet) had higher odds of uterine hyperstimulation with FHR changes than 31 other active interventions (180 studies).</td>
</tr>
<tr>
<td></td>
<td>• Not currently recommended for IOL where a live birth is expected</td>
</tr>
<tr>
<td></td>
<td>o Not included on the Queensland Health List of Approved Medicines (LAM) for IOL with a viable baby</td>
</tr>
</tbody>
</table>
4.1 Balloon (transcervical) catheter

Balloon catheters (e.g. Foley, Cooks) are used to ripen the cervix through applying pressure on the internal os of the cervix, thereby stretching the lower uterine segment and increasing local prostaglandin secretion.9

Table 15. Balloon catheter considerations

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Clinical practice point</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indications</strong></td>
<td>• Unfavourable cervix (MBS of 6 or less)</td>
</tr>
<tr>
<td></td>
<td>• May be considered with previous CS</td>
</tr>
<tr>
<td></td>
<td>• May be used following dinoprostone when there has been no/minimal effect on cervical ripening and ARM is not technically possible</td>
</tr>
<tr>
<td></td>
<td>• May be preferred where a reduced risk of uterine hyperstimulation is desirable (e.g. SGA, grand multipara, scarred uterus)</td>
</tr>
<tr>
<td><strong>Contraindication</strong></td>
<td>• Any contraindication to vaginal birth (e.g. malpresentation, abnormal placentation, HIV, active genital herpes)</td>
</tr>
<tr>
<td></td>
<td>• Any contraindications to IOL</td>
</tr>
<tr>
<td></td>
<td>• Ruptured membranes</td>
</tr>
<tr>
<td></td>
<td>• Undiagnosed bleeding</td>
</tr>
<tr>
<td></td>
<td>• Simultaneous use of prostaglandins and/or oxytocin</td>
</tr>
<tr>
<td></td>
<td>• Low lying placenta</td>
</tr>
<tr>
<td></td>
<td>• Polyhydramnios</td>
</tr>
<tr>
<td></td>
<td>• Abnormal FHR auscultation or CTG</td>
</tr>
<tr>
<td><strong>Relative contraindications</strong></td>
<td>• Antepartum bleeding</td>
</tr>
<tr>
<td></td>
<td>• Lower tract genital infection</td>
</tr>
<tr>
<td></td>
<td>• Fetal head not engaged (4/5 or 5/5 above the pelvic brim)</td>
</tr>
<tr>
<td><strong>Benefit</strong></td>
<td>• When compared to vaginal prostaglandins:</td>
</tr>
<tr>
<td></td>
<td>o Less uterine hyperstimulation and tachysystole</td>
</tr>
<tr>
<td></td>
<td>o No difference in CS rate</td>
</tr>
<tr>
<td></td>
<td>• No difference in overall number not achieving vaginal birth within 24 hours, although among multiparous women the risk of not birthing within 24 hours was higher</td>
</tr>
<tr>
<td></td>
<td>• Low cost and no specific storage or temperature requirements</td>
</tr>
<tr>
<td></td>
<td>• No evidence of an increased risk of infection although data is limited</td>
</tr>
<tr>
<td><strong>Risk</strong></td>
<td>• Placental abruption</td>
</tr>
<tr>
<td></td>
<td>• Uterine rupture</td>
</tr>
<tr>
<td></td>
<td>• Device entrapment</td>
</tr>
<tr>
<td></td>
<td>• Maternal discomfort during and after insertion</td>
</tr>
<tr>
<td></td>
<td>• Failed dilatation and inability to perform ARM</td>
</tr>
<tr>
<td></td>
<td>• Cervical laceration or ischaemia (if prolonged use)</td>
</tr>
<tr>
<td></td>
<td>• There is limited data comparing single to double balloon catheter</td>
</tr>
</tbody>
</table>

87, 88
### 4.1.1 Balloon (transcervical) catheter insertion

Table 16. Balloon catheter insertion procedure

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Clinical practice point</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Equipment</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Speculum&lt;br&gt;- Balloon catheter, either&lt;br&gt;  - 16/18 gauge catheter with double balloon (e.g. Cook cervical ripening balloon)&lt;br&gt;  - 26 French gauge Foley catheter&lt;br&gt;  - Sponge forceps&lt;br&gt;  - Sterile water or 0.9% sodium chloride (200 mL)&lt;br&gt;  - Syringe (20 mL)&lt;br&gt;  - Sterile lubricating gel&lt;br&gt;  - Swabs&lt;br&gt;  - Tape&lt;br&gt;  - CTG monitor&lt;br&gt;  - Bed with stirrups&lt;br&gt;  - Chlorhexidine</td>
</tr>
<tr>
<td><strong>Procedure</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Prior to commencement&lt;br&gt;  - Ensure pre IOL assessment complete including baseline observations&lt;br&gt;  - Encourage voiding&lt;br&gt;  - Performed by competent medical or midwifery staff&lt;br&gt;  - Contact a more experienced clinician if there are 2 unsuccessful attempts</td>
</tr>
<tr>
<td><strong>Prepare the balloon catheter</strong></td>
<td>- Stylet used with double balloon:&lt;br&gt;  - Loosen the fitting on the proximal hub of the stylet so that the distal tip of the stylet is even with the distal tip of the balloon&lt;br&gt;  - Tighten the fitting so that the wire does not move during manipulation&lt;br&gt;  - Seat the adjustable handle firmly into the blue port labelled “S”</td>
</tr>
<tr>
<td><strong>Insertion</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Digital placement of the catheter is less painful than using a speculum&lt;br&gt;  - Pass the balloon catheter through the internal os of the cervix using sponge forceps to assist&lt;br&gt;  - If insertion is technically difficult:&lt;br&gt;    - Consider the lithotomy position&lt;br&gt;    - Insert speculum and visualise the cervix&lt;br&gt;    - Clean the cervix with chlorhexidine&lt;br&gt;    - Pass the catheter through the cervix (using sponge forceps) until both balloons have entered the cervical canal</td>
</tr>
<tr>
<td><strong>Double balloon inflation</strong></td>
<td>- Once the catheter has traversed the cervix and the uterine balloon is above the internal os, remove the stylet (if used) before advancing the catheter further&lt;br&gt;  - Inflate the uterine balloon with 40 mL of sterile water or 0.9% sodium chloride&lt;br&gt;  - Gently pull the catheter back until the uterine balloon is against the internal cervical os&lt;br&gt;  - The vaginal balloon is now visible/palpable outside the external cervical os and is inflated with 20 mL of water or 0.9% sodium chloride&lt;br&gt;  - Once the balloons are situated on either side of the cervix, remove the speculum (if used) and add water or 0.9% sodium chloride up to a maximum of 80 mL per balloon&lt;br&gt;  - Document the inflation volume</td>
</tr>
<tr>
<td><strong>Single balloon inflation</strong></td>
<td>- Spigot the catheter&lt;br&gt;  - Inflate the balloon with 30–80 mL sterile water or 0.9% sodium chloride&lt;br&gt;  - Gently withdraw the catheter until the balloon rests against the internal os&lt;br&gt;  - Proximal end of the catheter may be taped to the thigh to provide constant, moderate tension of the balloon&lt;br&gt;  - Document the inflation volume</td>
</tr>
</tbody>
</table>
4.1.2 Balloon (transcervical) catheter post insertion care

Table 17. Post balloon catheter insertion

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Clinical practice point</th>
</tr>
</thead>
</table>
| **Monitoring**             | • Pulse, BP, FHR, uterine activity, engagement of the fetal head and vaginal loss:  
   o Immediately following balloon catheter insertion  
   o At 30 minutes post balloon catheter insertion  
   o Medical review required if malpresentation or fetal head 5/5 palpable after insertion  
   • CTG not required, unless other indications (e.g. uterine activity)  
   • Ongoing monitoring as for latent first stage of labour while:  
     o Observations are normal  
     o No contractions  
     o Not otherwise indicated  
     ▪ Refer to Queensland Clinical Guideline: *Normal Birth*[^99] |
| 12 hour reassessment       | • Schedule assessment 12 hours after insertion with plan to ARM  
   • If the balloon catheter has not spontaneously fallen out and ARM is unsuccessful:  
     o Obstetric review is indicated  
     o Continuing IOL may involve dinoprostone or reinsertion of another balloon catheter after 24 hours  
   • If there is a delay in the scheduled 12 hour assessment, remove the balloon catheter no later than 18 hours after insertion |
| Indications for birth suite care | • Observations abnormal  
   • Persistent pain and discomfort  
   • Spontaneous rupture of membranes  
   • Labour commences |
| Moderate or severe discomfort | • Assess for labour  
   • Reduce balloon volume (discuss with experienced clinician as required):  
     o Foley catheter: remove maximum of 10 mL  
     o Double balloon catheter: remove 10 mL from each vaginal and uterine balloon (from green stopcock marked ‘V’ and from red stopcock marked ‘U’)  
     o Reassess and repeat ensuring a minimum of 50 mL of residual volume remains in each balloon  
     o Document the volume removed  
   • Offer analgesia and sedation if woman not in labour and continues to experience moderate to severe discomfort despite balloon deflation  
   • If persistent pain and discomfort following oral analgesia  
     o Review by an obstetrician, or  
     o Transfer to birth suite for further assessment |
| Indications for early removal of balloon catheter | • Spontaneous rupture of membranes (SROM)  
   • Uterine hyperstimulation  
   • Maternal request |
| Difficulty passing urine   | • Offer appropriate analgesia and comfort aids  
   • If still unable to void, consider removing 10 mL of fluid from each of the uterine and vaginal balloons  
   • Note: Balloon may be in the vagina |
| If balloon catheter falls out | • Transfer to birth suite  
   • Perform VE  
     o Plan ARM and oxytocin as soon as possible (due to the temporary dilatory effect of balloon catheters) |
| Removal of balloon catheter | • After 12 hours remove the balloon catheter by completely deflating the balloon(s) using an appropriately sized syringe (do not leave balloon catheter insitu longer than 18 hours)  
   • Once the balloon catheter has been removed, perform an ARM and commence an oxytocin infusion |
4.2 Dinoprostone

Prostaglandins promote cervical ripening and stimulate uterine contractions. Dinoprostone is the most commonly used prostaglandin agent in third trimester IOL. Dinoprostone preparations include:
- Vaginal gel (prostaglandin E2, (prostin) 1 mg and 2 mg
- Controlled release vaginal pessary (cervidil)
- Refer to Table 18 and Table 19

Table 18. Dinoprostone considerations and dose

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Clinical practice point</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indication</strong></td>
<td>• Unfavourable cervix(^91)</td>
</tr>
<tr>
<td></td>
<td>• May be used following balloon catheter when there has been no/minimal effect on cervical ripening and artificial rupture of membranes (ARM) is not technically possible</td>
</tr>
<tr>
<td><strong>Contraindication</strong></td>
<td>• Known hypersensitivity to dinoprostone</td>
</tr>
<tr>
<td></td>
<td>• Ruptured membranes</td>
</tr>
<tr>
<td></td>
<td>• Grand multiparity</td>
</tr>
<tr>
<td></td>
<td>• Previous CS or any uterine surgery</td>
</tr>
<tr>
<td></td>
<td>• Malpresentation/high presenting part</td>
</tr>
<tr>
<td></td>
<td>• Unexplained PV bleeding during current pregnancy</td>
</tr>
<tr>
<td></td>
<td>• Abnormal CTG/fetal compromise</td>
</tr>
<tr>
<td><strong>Cautions(^91)</strong></td>
<td>• Multiple pregnancy</td>
</tr>
<tr>
<td></td>
<td>• Asthma, chronic obstructive pulmonary disease—may cause bronchospasm</td>
</tr>
<tr>
<td></td>
<td>• Epilepsy</td>
</tr>
<tr>
<td></td>
<td>• Cardiovascular disease</td>
</tr>
<tr>
<td></td>
<td>• Raised intraocular pressure, glaucoma</td>
</tr>
<tr>
<td></td>
<td>• Avoid combining with oxytocin [refer to Section 4.4 Oxytocin]</td>
</tr>
<tr>
<td><strong>Risk/benefit</strong></td>
<td>• Nausea, vomiting and diarrhea may occur soon after insertion(^91)</td>
</tr>
<tr>
<td></td>
<td>• Vaginal PGE(_2) compared to a placebo or expectant management(^90):</td>
</tr>
<tr>
<td></td>
<td>o Increased vaginal birth within 24 hours with repeated doses</td>
</tr>
<tr>
<td></td>
<td>o Increased hyperstimulation with FHR changes (4.8% versus 1.0%, RR 3.16, 95%CI 1.67 to 5.98)</td>
</tr>
<tr>
<td></td>
<td>o Did not appear to reduce CS rate, NICU admission, serious maternal/newborn morbidity/mortality</td>
</tr>
<tr>
<td><strong>Before administration</strong></td>
<td>• Ensure pre IOL assessment complete</td>
</tr>
<tr>
<td></td>
<td>• Encourage to empty bladder</td>
</tr>
</tbody>
</table>

Dinoprostone gel dose

**Initial dose:**
- Nulliparous: 2 mg PV
- Multiparous: 1 mg PV

**Repeat dose** (if clinically indicated and only after 6 hours)
- Nulliparous: 2 mg
- Multiparous: 1–2 mg

Do not give the repeat dose within 6 hours of the initial dose (i.e. so the maximum dose of 3 mg in a six hour period is not exceeded)

Dinoprostone pessary dose

- 10 mg PV (released at a rate of approximately 4 mg in 12 hours)\(^93\)
- A second dose is not recommended
### 4.2.1 Dinoprostone administration

#### Table 19. Dinoprostone administration

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Dinoprostone administration</th>
</tr>
</thead>
</table>
| **Administration**            | • Maternal and fetal safety outcomes do not seem to differ whether prostaglandins are administered in the morning or evening, but women may prefer morning administration<sup>94</sup>  
  • Pessary use may avoid repeated application of the gel  
  • Gel may be more appropriate where cervix is favourable<sup>1</sup> |
| **Dinoprostone gel**<sup>92</sup> | • Use water soluble lubricants (not obstetric cream)  
  • Remove from refrigeration and stand at room temperature for at least 30 minutes prior to use  
  • Insert high into the posterior fornix of the vagina  
  • Not for intracervical administration  
  • Advise recumbent or left lateral position for 30 minutes after insertion |
| **Dinoprostone pessary**<sup>93</sup> | • Remove from freezer or fridge immediately prior to use  
  • Can be stored in the refrigerator for up to one month (2–8 °C) after removal from the freezer  
  • Warming is not required  
  • Open only after decision has been made to use the pessary  
  • Use water soluble lubricant (not obstetric cream)  
  • Insert and position transversely in the posterior fornix of the vagina:  
    - To minimise potential for the pessary to fall out and subsequent insufficient dinoprostone exposure  
    - Ensure sufficient tape outside vagina to allow removal  
  • Woman to remain recumbent for 30 minutes  
  • Advise to report if pessary falls out |
| **Monitoring post insertion** | • Temperature, pulse, respiratory rate, BP, FHR, uterine activity, and vaginal loss  
    - Immediately after insertion  
    - Hourly for 4 hours  
  • Perform CTG after insertion (minimum 30 minutes)  
  • Advise to inform staff as soon as contractions commence  
  • Ongoing monitoring as for latent first stage of labour while:  
    - Observations are normal  
    - No contractions  
    - Not otherwise indicated  
    - **Refer to Queensland Clinical Guideline: Normal birth<sup>89</sup>**  
    - When in active labour—continuous CTG<sup>59</sup> |
| **Assessment of progress**    | • Reassess the MBS:  
    - Gel—wait at least 6 hours after insertion<sup>91</sup>  
    - Pessary—wait at least 12 hours after insertion<sup>91</sup>  
  • Irrespective of MBS, recommend ARM if technically possible<sup>95,96</sup>  
  • If ARM not possible, repeat gel dose may be required (following reassuring CTG) |
| **Indications for removal: dinoprostone pessary**<sup>93</sup> | • Onset of regular, painful uterine contractions, occurring every 3 minutes irrespective of any cervical change  
  • Membranes rupture (spontaneous or ARM)  
  • Fetal distress  
  • Uterine hyperstimulation or hypertonic uterine contractions  
  • Maternal systemic adverse PGE<sub>2</sub> effects (e.g. nausea, vomiting, hypotension, tachycardia)  
  • If starting oxytocin infusion—remove at least 30 minutes prior to starting  
  • Insufficient cervical ripening after 12 hours |
### 4.3 Artificial rupture of membranes

#### Table 20. Artificial rupture of membranes

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Clinical practice point</th>
</tr>
</thead>
</table>
| **Indication**            | • Favourable cervix (MBS of 7 or more)\(^9,37\)  
  • ARM alone is not recommended as time to onset of contractions is unpredictable\(^6\), particularly in nulliparous women [refer to Section 4.4 Oxytocin]  
  • To observe the colour and amount of liquor when clinically indicated |
| **Relative contraindication** | • Poor application of the presenting part/ unstable lie\(^9\)  
  • Fetal head not engaged\(^9\) (5/5 above the pelvic brim) |
| **Risk/benefit**          | • Risk of: cord prolapse\(^9\) or compression\(^35\), rupture of vasa praevia\(^97\), pain and discomfort\(^9\) [refer to Section 5]  
  • ARM and immediate oxytocin compared to ARM and delayed oxytocin (commenced 4 hours post ARM) showed shorter ARM to birth interval in nulliparous\(^96,99\) and parous women\(^100\)  
  • Compared to amniotomy alone, ARM and oxytocin resulted in fewer women not birthing vaginally at 24 hours\(^97\)  
  • Following cervical priming, early ARM (performed regardless of MBS) has been associated with a decrease in IOL to birth interval and no difference in other outcomes\(^96,98\) |
| **Before procedure**      | • If no other IOL procedure before ARM, perform pre IOL assessment  
  • Encourage to empty bladder  
  • Abdominal palpation to determine descent\(^101\), position and presentation  
  • VE to determine stage of labour, MBS, presentation, position and descent, possible cord or malpresentation, identify membranes  
  • Consult obstetrician if the head is not engaged\(^101\), or cord presentation, malpresentation, unstable lie or polyhydramnios |
| **Procedure (continuing on from assessment VE)** | • Maintain digital contact with presenting part  
  • Insert amnioskirt–amnicot, using examining finger as guard to hook  
  • Rupture forewaters–avoid ARM over fontanelle or face  
  • Remove amnioskirt–amnicot, guarding it against index finger  
  • Confirm passage of fluid and check for presence of blood or meconium  
  • Sweep membranes from presenting part  
  • Ensure good application of presenting part before completing VE  
  • Apply fetal scalp electrode, only if clinically indicated  
  • Refer to Queensland Clinical Guideline: *Intrapartum fetal surveillance*\(^69\)  
  • Following ARM for IOL, recommend commencement of oxytocin immediately\(^9\)  
  • Document abdominal palpation and VE findings |
| **Post ARM monitoring**   | • FHR, uterine activity, and vaginal loss (liquor amount, colour and consistency) immediately after ARM  
  • If oxytocin commenced immediately after ARM, then monitor as for oxytocin [refer Section 4.4 Oxytocin]  
  • If oxytocin not commenced immediately after ARM (e.g. woman wishes to await onset of contractions), then ongoing monitoring as for latent first stage of labour while:  
  o Observations are normal  
  o No contractions  
  o Not otherwise indicated  
  o Refer to Queensland Clinical Guideline: *Normal birth*\(^69\)  
  • If FHR or liquor abnormalities (e.g. meconium/blood stained or no liquor):  
  o Perform CTG  
  o Discuss/refer/consult as indicated  
  • Refer to Queensland Clinical Guideline: *Intrapartum fetal surveillance*\(^69\)  
  • Encourage mobilisation to promote onset of uterine contractions
4.4 **Oxytocin**

Oxytocin stimulates the smooth muscle of the uterus to produce rhythmic contractions.

**Table 21. Oxytocin**

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Clinical practice point</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Indication</strong></td>
<td>• IOL in the setting of ruptured membranes</td>
</tr>
</tbody>
</table>
| **Cautions**            | • Due to the additive uterine effects, do not commence oxytocin within 91:  
  - Six (6) hours of dinoprostone vaginal gel administration  
  - 30 minutes of removal of dinoprostone vaginal pessary  
  - Discuss with an obstetrician prior to commencement with:  
    - Previous uterine surgery (e.g. CS) [refer to Queensland Clinical Guideline: Vaginal birth after caesarean section 25]  
    - Multiple pregnancy  
    - Greater than four previous births  
    - Cardiovascular disease |
| **Risk/benefit**        | • Tachysystole or hypertonus with/without signs of FHR abnormalities  
  - Refer to Section 5 Risks and benefits associated with IOL  
  - Nausea and vomiting (0.1 to 1%) 91  
  - Rarely (less than 0.1%): arrhythmias, anaphylactoid reaction, severe (tetanic) uterine contraction leading to uterine rupture, flushing, electrocardiograph (ECG) changes (including prolonged QT interval), transient hypotension, reflex tachycardia (common with rapid IV injection) |
| **Medication safety**   | • The standard oxytocin preparation and administration regimen is recommended for all Queensland facilities as outlined in Section 4.4.1 Oxytocin regimen administration  
  • If required, the same infusion solution can be continued for PPH management and as PPH prophylaxis following CS |
| **Before administration** | • Verify CTG normal  
  • If membranes are not ruptured, perform ARM prior to oxytocin infusion  
  • If SROM ensure forewaters are ruptured |
| **Monitoring**          | • Provide one-to-one midwifery care 103  
  • Commence the intrapartum record when infusion is commenced  
  • Maternal and fetal observations as per first stage of active labour [refer to Queensland Clinical Guideline: Normal birth 89]  
  • Commence continuous CTG at the onset of first contractions  
    - Refer to Queensland Clinical Guideline: Intrapartum fetal surveillance 69  
  • Maternal pulse and FHR prior to any increase in the infusion rate 102  
  • Monitor fluid balance as water intoxication/hyponatraemia may result from prolonged infusion 102 (rare with the use of isotonic solutions 104)  
  • Planned VBAC—maintain vigilance for uterine dehiscence and rupture |
4.4.1 Oxytocin regimen administration

Table 22. Oxytocin administration

<table>
<thead>
<tr>
<th>Aspect</th>
<th>Clinical practice point</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Administration</strong></td>
<td><strong>• Add oxytocin 30 International units to a 500 mL bag of either 0.9% sodium chloride or compound sodium lactate (Hartmann’s solution)</strong>&lt;br&gt;○ 1 milliunit/minute = 1 mL/hour&lt;br&gt;<strong>• Use a volumetric pump to ensure an accurate rate of infusion</strong>&lt;br&gt;○ Program delivery pumps for correct infusion concentrations&lt;br&gt;○ Administer oxytocin by sideline/secondary IV access (as oxytocin infusion initiated at low volume)&lt;br&gt;<strong>• Record the dose in milliunit per minute</strong>&lt;br&gt;<strong>• Increase dose at 30 minute or longer intervals</strong>&lt;br&gt;<strong>• Aim for 3–4 contractions in a 10 minute period with duration of 40–60 seconds and resting period not less than 60 seconds</strong>&lt;br&gt;<strong>• Titrate dose against uterine contractions and FHR</strong>&lt;br&gt;<strong>• Use the minimum dose required to establish and maintain active labour</strong>&lt;br&gt;<strong>• Mark changes to dose clearly and contemporaneously on the intrapartum record and/or CTG</strong></td>
</tr>
<tr>
<td><strong>Discontinue/recommence</strong></td>
<td><strong>• After labour is established (cervical dilation greater than or equal to 5 cm) oxytocin infusion may be electively discontinued</strong>&lt;br&gt;○ Reduced incidence of FHR abnormalities and uterine hyperstimulation reported&lt;br&gt;○ Inconsistent evidence about effect on active phase duration (possibly increased)&lt;br&gt;<strong>• If recommencing infusion and no local protocol, use the following guide:</strong>&lt;br&gt;○ If ceased for less than 30 minutes, recommence at half previous rate&lt;br&gt;○ If ceased for longer than 30 minutes, recommence at initial starting dose (due to short half-life)<strong>&lt;br&gt;</strong>• Prior to exceeding 20 milliunit/minute (manufacturer recommended maximum)<strong>&lt;br&gt;</strong>• At the maximum regimen dose of 32 milliunit/minute and labour not commenced**&lt;br&gt;<strong>• If infusion ceased or recommenced</strong></td>
</tr>
<tr>
<td><strong>Obstetrician review</strong></td>
<td><strong>• The ideal dosing regimen of oxytocin is unknown but there are well recognised complications</strong>&lt;br&gt;○ Refer to Section 5 Risks and benefits associated with IOL&lt;br&gt;<strong>• Only vary the regimen (milliunit/minute, rate of increase and/or maximum dose) following an assessment by an obstetrician of the individual clinical circumstances and progress of labour</strong>&lt;br&gt;○ Processes and systems that facilitate routine variation are not recommended</td>
</tr>
</tbody>
</table>

Table 23. Oxytocin regimen

<table>
<thead>
<tr>
<th>Time after starting (minutes)</th>
<th>Dose (milliunit/minute)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td>30</td>
<td>2</td>
</tr>
<tr>
<td>60</td>
<td>4</td>
</tr>
<tr>
<td>90</td>
<td>8</td>
</tr>
<tr>
<td>120</td>
<td>12</td>
</tr>
<tr>
<td>150</td>
<td>16</td>
</tr>
<tr>
<td>180</td>
<td>20</td>
</tr>
</tbody>
</table>

**Infusion: oxytocin**<br>(30 International units in 500 mL)<br>1 milliunit/minute is equal to 1 mL/hour

**Prior to exceeding 20 milliunit/minute:**<br>Obstetrician review required

<table>
<thead>
<tr>
<th>Time (minutes)</th>
<th>Dose (milliunit/minute)</th>
</tr>
</thead>
<tbody>
<tr>
<td>210</td>
<td>24</td>
</tr>
<tr>
<td>240</td>
<td>28</td>
</tr>
<tr>
<td>270</td>
<td>32</td>
</tr>
</tbody>
</table>
## 5 Risks and benefits associated with IOL

Table 24. Risks and benefits associated with IOL

<table>
<thead>
<tr>
<th>Risk</th>
<th>Clinical practice point</th>
</tr>
</thead>
</table>
| Failed IOL<sup>1</sup>                    | • The criteria for failed IOL are not generally agreed  
• Review the individual clinical circumstances  
• Assess fetal wellbeing using CTG  
• Discuss options for care  
• The likelihood of vaginal birth is significantly lower if not in active labour after 12 hours of oxytocin<sup>108</sup>  
• If appropriate consider:  
  o An alternative IOL method, and/or  
  o Discharge home for 24 hours followed by second attempt at IOL  
  o Caesarean section |
| Tachysystole or hypertonus (without FHR abnormalities) OR Uterine hyperstimulation (with FHR abnormalities) | • Escalate as required and according to local protocols  
• Continuous CTG  
• Attempt removal of any remaining dinoprostone gel  
• Remove dinoprostone pessary if still in situ<sup>91</sup>  
• Cease/reduce rate of oxytocin infusion<sup>1</sup> while reassessing labour and fetal state  
• Position left lateral  
• Record maternal observations, including BP  
• Commence intravenous (IV) fluids via new administration set  
• VE to assess cervical dilation and exclude cord prolapse  
• If persists, consider use of tocolytic<sup>1</sup>:  
  o Terbutaline: 250 micrograms subcutaneously or  
  o Terbutaline: 250 micrograms in 5 mL IV over 5 minutes<sup>3</sup>  
  o Salbutamol: 100 micrograms by slow IV injection<sup>3</sup>  
  o *Sublingual Glyceril Trinitrate (GTN) spray 400 micrograms<sup>3</sup>  
  o Excessive uterine activity in the absence of evidence of fetal compromise is not in itself an indication for tocolysis<sup>1</sup>  
  • If clinically indicated, prepare for instrumental birth or CS<sup>1</sup> (e.g. FHR does not return to normal) |
| Cord prolapse<sup>1</sup>                  | • A potential risk at the time of membrane rupture especially when the membranes are ruptured artificially  
• To reduce the likelihood of cord prolapse:  
  o Before ARM, assess engagement of the presenting part  
  o If the baby’s head is high, avoid ARM  
  o Palpate for umbilical cord presentation during the VE  
  o Avoid dislodging the baby’s head during the VE |
| Uterine rupture                            | • An uncommon event with IOL<sup>1</sup>  
• A life-threatening event for mother and baby  
• If suspected, prepare for an emergency CS,<sup>1</sup> uterine repair or hysterectomy |
| PPH                                        | • IOL with oxytocin has been associated with an increased risk of PPH<sup>109</sup>  
• Refer to Queensland Clinical Guideline: Primary postpartum haemorrhage<sup>109</sup> |
| Increased intervention                     | • Compared with spontaneous labour, IOL may be associated with a higher incidence of additional interventions (e.g. electronic fetal monitoring, analgesia usage), although there is no increase in instrumental births<sup>110-112</sup> or CS<sup>113-116</sup> in randomised controlled trials  
• Compared with expectant management, no association found between IOL and increased rates of adverse perinatal outcomes of neonatal unit admission, maternal death, or meconium stained amniotic fluid<sup>8-10</sup> |
| Benefits                                   | • When performed for a valid indication, IOL should result in a reduction in perinatal morbidity/mortality  
• Limited evidence suggests women may prefer IOL to expectant management (serial antenatal monitoring) beyond 41 weeks<sup>14</sup> |

*Not currently listed on the Queensland Health List of Approved Medications (LAM), not Therapeutics Good Administration (TGA) approved for this purpose.
References


Acknowledgements

Queensland Clinical Guidelines gratefully acknowledge the contribution of Queensland clinicians and other stakeholders who participated throughout the guideline development process particularly:

**Working Party Clinical Lead**
Dr Michael Beckmann, Director Mothers Babies and Women's Health Services, Mater Health, Brisbane

**Queensland Clinical Guidelines Program Officers**
Ms Lyndel Gray, Clinical Nurse Consultant  
Ms Jacinta Lee, Program Manager

**Working Party Members**
Mrs Emma Archer, Clinical Midwife, Group Practice, Beaudesert Hospital  
Ms Rukhsana Aziz, Clinical Midwifery Consultant, Maternity, Ipswich Hospital  
Ms Rita Ball, Midwifery Educator, Cairns Hospital  
Mrs Stephanie Bethel, Caseload Midwife, Mareeba Hospital  
Dr Elize Bolton, Clinical Director, Obstetrics and Gynaecology, Bundaberg Hospital  
Miss Samantha Borchers, Registered Midwife, Maternity/Birth Suite, Gold Coast University Hospital  
Mrs Anne Bousfield, Clinical Midwifery Consultant, Maternity, Roma Hospital  
Dr Huba Brezovsky, Consultant Obstetrician and Gynaecologist, Mackay Base Hospital  
Ms Georgina Caldwell, Registered Midwife, Amity Midwifery Group Practice, Redcliffe  
Ms Jackie Chaplin, Nurse Educator Midwifery and Neonatal, West Moreton Hospital and Health Services  
Dr Lindsay Cochrane, Staff Specialist, Obstetrics and Gynaecology, Caboolture Hospital  
Mrs Kelly Cooper, Registered Midwife, Maternity, Caboolture Hospital  
Mrs Catherine Cooper, Practice Development Midwife, Mater Health, Brisbane  
Mrs Allison Davis, Midwife, Birth Centre, Mackay Base Hospital  
Dr Wendy Dutton, Director of Obstetrics and Gynaecology, Redland Hospital  
Miss Samantha Felts, Midwife, Maternity, Mount Isa Hospital  
Ms Judy Foote, Midwife, RN, Child Birth Educator/Child and Family Health Nurse, The Townsville Hospital  
Dr David Freidin, Intra-Partum Clinical Lead, Royal Women's and Brisbane Hospital  
Dr Nelson Gonzalez, Obstetrician and Gynaecologist, Gold Coast University Hospital  
Mrs Marceline Green, Consumer Representative, Maternity Consumer Network, Toowoomba  
Ms Marnie Griffiths, Midwifery Lecturer, Bachelor of Midwifery, Griffith University, Brisbane  
Mrs Pam Harsant, Nurse Unit Manager, Maternity, Hervey Bay Hospital  
Ms Jacinta Hay, Midwife, Birth Suite, Logan Hospital  
Ms Louise Homan, Nurse Unit Manager, Birth Suite, Cairns Hospital  
Ms Debbie Hambly, A/Midwifery Unit Manager, Maternity Unit, Caboolture Hospital  
Mrs Fiona, Kajewski, Clinical Midwife Consultant, Maternity Services, Toowoomba Hospital  
Dr Christopher, King, Director of Obstetrics and Gynaecology, Mount Isa Hospital  
Mrs Sarah Kirby, Midwifery Unit Manager, Birth Suite, Royal Brisbane and Women's Hospital  
Ms Janelle Laws, Nurse Educator, Royal Brisbane and Women's Hospital  
Mrs Gemma Macmillan, Clinical Midwife/Project Officer, The Townsville Hospital  
Dr Brian McCully, Director of Obstetrics and Gynaecology, Ipswich Hospital  
Mrs Michelle McElroy, Midwifery Educator, Maternity/Education, Mount Isa Hospital  
Miss Tina Meynell, Midwife, Birth Suite, Caboolture Hospital  
Ms Lyndall Mollart, Clinical Midwifery Consultant, Maternity Services, Rockhampton Hospital  
Mrs Marcia Morris, Midwifery Educator, Royal Brisbane and Women's Hospital  
Ms Lillian Newman, Clinical Midwife, Women and Birthing, Redland Hospital  
Ms Jacqueline O'Neill, Midwife, Women's and Children's Service, Toowoomba Hospital  
Dr Gino, Pecoraro, Obstetrician and Gynaecologist, Mater Health Services, Brisbane  
Ms Jenny Ramsay, Consumer Representative, Friends of the Birth Centre, Brisbane  
Miss Georgia Roehrig, Student Midwife, Maternity, Redland Hospital  
Ms, Pamela, Sepulveda, Clinical Midwifery Consultant, Birthing Suites, Logan Hospital  
Ms Alecia Staines, Consumer Representative, Maternity Consumer Network, Toowoomba  
Mrs Angela Swift, Clinical Midwifery Consultant, Mossman MPHS  
Mrs Bethan Townsend, Clinical Facilitator, Education Department, Gold Coast University Hospital  
Ms Nicole Utley, Midwife, Birth Centre, Royal Brisbane and Women's Hospital  
Dr Karen Whitfield, Senior Pharmacist, Royal Brisbane and Women's Hospital

**Queensland Clinical Guidelines Team**
Associate Professor Rebecca Kimble, Director  
Ms Jacinta Lee, Manager  
Ms Cara Cox, Clinical Nurse Consultant  
Ms Lyndel Gray, Clinical Nurse Consultant  
Ms Stephanie Sutherns, Clinical Nurse Consultant  
Dr Brent Knack, Program Officer  
Steering Committee

**Funding:** This clinical guideline was funded by Healthcare Improvement Unit, Queensland Health